Assessing the Quality of Life Using the Health Utilities Index Questionnaire in Children With Severe Persistent Asthma During the Treatment With Omalizumab

Намазова-Баранова, Л. С.; Вишнёва, Е. А.; Dobrynina, E. A.; Винярская, И В; Алексеева, А.А.; Chernikov, V.V.; Селимзянова, Л. Р.

doi:10.15690/pf.v14i5.1783

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Моноклональные антитела достаточно широко применяют у детей, конечно, прежде всего в иммунологии и ревматологии, онкологии и онкогематологии [28][29][30][31][32]. В то же время вопросы дозирования, как и общие фармакокинетические различия между взрослыми и детьми, остаются спорными.…”

Section: моноклональные антитела в педиатрии и неонатологииunclassified

The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View

Kolbin

Yemelyanova

2021

Pediatr. farmakol.

View full text Add to dashboard Cite

The article reviews monoclonal antibodies, its structure, classifications, pharmacodynamics, pharmacokinetics, and adverse effects. There are examples for each section. Approaches to the research and criteria for drug selection in paediatrics are discussed in detail: the role of clinical trials, extrapolation and pharmacometrics. It has been shown that the differences in the pharmacokinetics of monoclonal antibodies between adults and children present due to the age-related characteristics of various physiological processes. The authors analyse such parameters as absorption, bioavailability, distribution, and elimination. The role of monoclonal antibodies immunogenicity in the structure of adverse effects in children is fully presented. Pharmacometrics is reviewed in the form of modelling and simulation in monoclonal antibodies dosing in paediatrics. It is important to consider the growth and development as “moving targets" in pediatrics regardless the principle of monoclonal antibodies dosage in children. The conclusions were made, and the guidelines were prepared based on the article results.

show abstract

Section: моноклональные антитела в педиатрии и неонатологииunclassified

The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View

Kolbin

Yemelyanova

2021

Pediatr. farmakol.

View full text Add to dashboard Cite

show abstract

The effect of additional nutritional support as part of the rehabilitation program on the quality of life and morbidity in children with recurrent respiratory pathology

et al. 2018

View full text Add to dashboard Cite

Objective of the study: Assess the health and quality of life in children with recurrent respiratory pathology and justify the effectiveness of comprehensive rehabilitation program to improve health involving additional nutritional support.Materials and methods: 101 children aged 5–9 years with recurrent respiratory pathology received a non-comparative clinical examination and rehabilitation. The first group included 75 children with disorders of nutritional status that were identified upon results of physical examination, anthropometric measurements, including body composition analysis (bioimpedance measurement), biochemical parameters and actual nutrition evaluation. The observed children of the main group received «PediaSure with fiber» functional product as part of the complex rehabilitation therapy to replenish the diet with the basic nutrients, vitamins and trace elements. The second group of 26 children comparable in age and gender, but not having disorders of nutritional status was allocated in order to assess the impact of the nutritional deficiency on the severity of recurrent respiratory disease. Those children received only general health therapy and usual sanatorium traditional food. The effectiveness of the therapy was assessed on the basis of the positive dynamics of the nutritional status and the quality of life study using the questionnaire Pediatric Quality of Life Questionnaire (Generic Core Scales). The study was conducted in Duslyk children’s sanatorium in Ufa.Results: The comprehensive health improvement program and additional nutritional support in children with recurrent respiratory pathology showed a significant improvement in anthropometric data, a 2.5-fold decrease in the average number (from 7.12 to 2.9, p <0.05), and 1.8 -fold decrease in the average duration (from 11.88 to 6.76 days, p <0.05) of episodes of recurrent respiratory infections, and also allowed to achieve significant improvement in all parameters of the children’s quality of life.Conclusion: The comprehensive health improvement program and additional nutritional support in children with recurrent respiratory pathology contribute to improving the quality of life, increasing adaptive capacity, reducing the frequency and duration of acute respiratory infections.

show abstract

Personalised Medicine in Bronchial Asthma: Current Concepts and Prospects

FAYZULLINA¹,

VIKTOROV²,

GAFUROVA³

2021

View full text Add to dashboard Cite

Bronchial asthma (BA) is today a global medical and socio-economic issue in the health care system. Manifesting in childhood, the disease persists throughout the patient’s life, characterised by a variable clinical course. The periods of remission are combined with the periods of exacerbation and a wide range of symptoms ranging from mild symptoms to severe illness. Following the data of epidemiological studies, BA occupies a leading place among the chronic disorders of the lungs of non-infectious aetiology with increasing the annual prevalence trend. The article presents a literature review on the prospects for a personalised medicine (PM) approach for the group of socially significant, multifactorial diseases, including BA. Implementing PM for asthma patients makes it possible to diagnose and predict the disease even at the preclinical stage. This will reduce mortality, morbidity and disability rates, cut the costs of treatment and rehabilitation of symptomatic patients, and increase the patient’s adaptive capabilities, coping with outdoor environmental and local factors. Keywords: Bronchial asthma, personalised medicine, HealthNet program, P4 medicine concept.

show abstract

Assessing the Quality of Life Using the Health Utilities Index Questionnaire in Children With Severe Persistent Asthma During the Treatment With Omalizumab

Cited by 3 publications

References 9 publications

The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View

The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View

The effect of additional nutritional support as part of the rehabilitation program on the quality of life and morbidity in children with recurrent respiratory pathology

Personalised Medicine in Bronchial Asthma: Current Concepts and Prospects

Contact Info

Product

Resources

About